Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Lymphoproliferative disorders Clinical Trials

A listing of Lymphoproliferative disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (30) clinical trials

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Background Epstein-Barr virus (EBV) is a chronic viral infection associated with a heterogeneous group of lymphoproliferative disorders (LPD) and non-Hodgkin lymphomas (NHL) The shared pathobiology of EBV-positive LPDs and NHLs includes a defect in host mechanisms of immune tolerance and immunosurveillance. Programmed death-1 (PD-1) is a surface protein present on ...

Phase

Family Study of Lymphoproliferative Disorders

Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic ...

Phase N/A

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or ...

Phase N/A

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

STUDY OBJECTIVES Primary Objective (Phase Ib portion of Study) To establish a safe dose (ie, number cells/m2) of ATLCAR.CD30 to infuse after lymphodepletion with bendamustine in adult patients with CD30+ refractory/relapsed Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). To establish a safe dose (ie, number cells/m2) of ATLCAR.CD30 to infuse ...

Phase

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

The purpose of this study is to determine whether VRx-3996 in combination with valganciclovir is safe, determine the side effect profile, and to determine whether this therapy may help patients with EBV-related lymphomas. The study has two phases. Goals of the first phase include determining a safe and tolerable dose ...

Phase

Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies

Background Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Patients with PID can have life-threatening complications including malignancy, recurrent infection, and autoimmunity/immune dysregulation Allogeneic blood or marrow transplantation (allo BMT) has ...

Phase

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Patients who participate will be asked to complete detailed family and medical history questionnaires initially, with a follow-up questionnaire every year. Patients will be asked to supply a blood sample and possibly a mouthwash sample, both of which can be done by mail. Patients will be asked to consent to ...

Phase N/A

Treatment and Natural History Study of Lymphomatoid Granulomatosis

BACKGROUND Lymphomatoid granulomatosis (LYG) is an angiocentric destructive proliferation of lymphoid cells predominantly involving the lungs, skin, kidneys, and central nervous system. It is divided into three grades, depending on the degree of necrosis and cellular atypia. The grades of disease are histologically-based and do not necessarily correlate with clinical ...

Phase

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma GRALE

Subjects (or their syngeneic donor) will give blood for investigators to make LMP/BARF1/EBNA-1 (GRALE) CTLs in the lab. These cells will be grown and frozen for the subject. Patients will be started on the lowest dose (1 of 3 different levels) of GRALE T cells. Once that dose schedule proves ...

Phase

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

The investigators will draw blood from the subject to make EBV-specific cytotoxic T-lymphocytes (EBVSTs) in the lab. Investigators will make the cells by first growing a special type of cells called dendritic cells (DCs) or monocytes to stimulate the T cells. Then they will add specially produced mixtures of proteins ...

Phase